Tags : Atypical Hemolytic Uremic Syndrome

Alexion Reports Results of Ultomiris (ravulizumab-cwvz) in P-III Study in

Shots: The P-III study involves assessing of Ultomiris (IV) in complement inhibitor-naïve patients with aHUS, receiving dose based on their weight varying upto 3,600 mg for 2 years P-III study results: reduction in thrombocytopenia in 83.9% patients; reduction in hemolysis in 76.8% patients; improved kidney function in 58.9% patients; No case of meningococcal infection observed; […]Read More